Effects of Trastuzumab Combined with Chemoradiotherapy on Serum CEA,CA153,ICAM-1 and Toxic Side Effects in Patients with HER2-positive Breast Cancer
Objective To investigate the effects of trastuzumab combined with chemoradiotherapy on carcinoembryonic antigen(CEA),cancer-associated glycoprotein antigen(CA153)and intercellular adhesion factor-1(ICAM-1)in human epider-mal growth factor receptor 2(HER2)positive breast cancer patients and their side effects.Methods According to the envelope drawing method,110 patients who treated with HER2-positive breast cancer were divided into the observation group(55 cases)and the control group(55 cases).The patients in the control group were treated with chemotherapy and radiotherapy.On the basis of the control group,the observation group was treated with Trastuzumab.The clinical efficacy,survival time and quality,serum tumor marker levels and drug safety of the 2 groups were compared.Results The remission rate of disease in the control group(43.64％)after treatment was significantly lower than that in the observation group(76.36％)(P＜0.05).The overall tumor survival,progression-free survival and QOL scores of the control group were significantly lower than those of the observation group(P＜0.05).After treatment,CEA,CA153 and ICAM-13 were decreased in both groups,and the decrease was more significant in the observation group(P＜0.05).There was no significant difference in the incidence of adverse reactions between the observa-tion group(27.27％)and the control group(23.64％)(P＞0.05).Conclusion Trastuzumab combined with chemoradiotherapy can effectively improve the serum CEA,CA153 and ICAM-1 levels of patients with HER2-positive breast cancer,and improve the clinical efficacy of patients with HER2-positive breast cancer,without increasing the toxic and side effects of patients.
TrastuzumabChemoradiotherapyHer2-positive breast cancerSerum CEA,CA153,ICAM-1Toxic and side effects
NETL
NSTL
万方数据
